Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy
- PMID: 23532477
- PMCID: PMC3689341
- DOI: 10.1093/cid/cit195
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy
Abstract
Background: Combination antiretroviral therapy (cART) reduces genital tract human immunodeficiency virus type 1 (HIV-1) load and reduces the risk of sexual transmission, but little is known about the efficacy of cART for decreasing genital tract viral load (GTVL) and differences in sex or HIV-1 subtype.
Methods: HIV-1 RNA from blood plasma, seminal plasma, or cervical wicks was quantified at baseline and at weeks 48 and 96 after entry in a randomized clinical trial of 3 cART regimens.
Results: One hundred fifty-eight men and 170 women from 7 countries were studied (men: 55% subtype B and 45% subtype C; women: 24% subtype B and 76% subtype C). Despite similar baseline CD4(+) cell counts and blood plasma viral loads, women with subtype C had the highest GTVL (median, 5.1 log10 copies/mL) compared to women with subtype B and men with subtype C or B (4.0, 4.0, and 3.8 log10 copies/mL, respectively; P < .001). The proportion of participants with a GTVL below the lower limit of quantification (LLQ) at week 48 (90%) and week 96 (90%) was increased compared to baseline (16%; P < .001 at both times). Women were significantly less likely to have GTVL below the LLQ compared to men (84% vs 94% at week 48, P = .006; 84% vs 97% at week 96, P = .002), despite a more sensitive assay for seminal plasma than for cervical wicks. No difference in GTVL response across the 3 cART regimens was detected.
Conclusions: The female genital tract may serve as a reservoir of persistent HIV-1 replication during cART and affect the use of cART to prevent sexual and perinatal transmission of HIV-1.
Keywords: HIV-1 genital tract RNA; HIV-1 subtypes B and C; antiretroviral drugs.
Figures

References
-
- Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921–9. - PubMed
-
- Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394–402. - PubMed
-
- Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341:385–93. - PubMed
-
- John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis. 2001;183:206–12. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AI069436/AI/NIAID NIH HHS/United States
- U01 AI069476/AI/NIAID NIH HHS/United States
- AI069438/AI/NIAID NIH HHS/United States
- P30 AI027757/AI/NIAID NIH HHS/United States
- U01 AI069424/AI/NIAID NIH HHS/United States
- AI069432/AI/NIAID NIH HHS/United States
- UM1 AI069436/AI/NIAID NIH HHS/United States
- AI68634/AI/NIAID NIH HHS/United States
- AI69467/AI/NIAID NIH HHS/United States
- UM1 AI069423/AI/NIAID NIH HHS/United States
- U01 AI069467/AI/NIAID NIH HHS/United States
- U01 AI069423/AI/NIAID NIH HHS/United States
- U01 AI069438/AI/NIAID NIH HHS/United States
- U01 AI027661/AI/NIAID NIH HHS/United States
- UM1 AI069476/AI/NIAID NIH HHS/United States
- UM1 AI069424/AI/NIAID NIH HHS/United States
- U01 AI069463/AI/NIAID NIH HHS/United States
- UM1 AI069432/AI/NIAID NIH HHS/United States
- AI069463/AI/NIAID NIH HHS/United States
- UM1 AI069438/AI/NIAID NIH HHS/United States
- UM1 AI069495/AI/NIAID NIH HHS/United States
- AI38858/AI/NIAID NIH HHS/United States
- UM1 AI069471/AI/NIAID NIH HHS/United States
- U01 AI069439/AI/NIAID NIH HHS/United States
- AI046370/AI/NIAID NIH HHS/United States
- UM1 AI069428/AI/NIAID NIH HHS/United States
- UM1 AI069439/AI/NIAID NIH HHS/United States
- AI069423/AI/NIAID NIH HHS/United States
- U01 AI069428/AI/NIAID NIH HHS/United States
- AI069439/AI/NIAID NIH HHS/United States
- AI069428/AI/NIAID NIH HHS/United States
- UM1 AI069412/AI/NIAID NIH HHS/United States
- UM1 AI068634/AI/NIAID NIH HHS/United States
- AI069495/AI/NIAID NIH HHS/United States
- UM1 AI069518/AI/NIAID NIH HHS/United States
- U01 AI069432/AI/NIAID NIH HHS/United States
- U01 AI038858/AI/NIAID NIH HHS/United States
- AI027661/AI/NIAID NIH HHS/United States
- U01 AI046370/AI/NIAID NIH HHS/United States
- U01 AI068636/AI/NIAID NIH HHS/United States
- U01 AI069518/AI/NIAID NIH HHS/United States
- AI069424/AI/NIAID NIH HHS/United States
- UM1 AI069463/AI/NIAID NIH HHS/United States
- U01 AI069495/AI/NIAID NIH HHS/United States
- UL1 TR000457/TR/NCATS NIH HHS/United States
- U01AI068636/AI/NIAID NIH HHS/United States
- UM1 AI069467/AI/NIAID NIH HHS/United States
- U01 AI069436/AI/NIAID NIH HHS/United States
- AI069476-01/AI/NIAID NIH HHS/United States
- AI069518/AI/NIAID NIH HHS/United States
- AI069471/AI/NIAID NIH HHS/United States
- U01 AI069471/AI/NIAID NIH HHS/United States
- U01 AI068634/AI/NIAID NIH HHS/United States
- P30 AI050410/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials